SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo Weijing Sun, MD

Professor of Medicine

Director of GI Cancers Section of Hematology-Oncology

Co-Director of UPMC GI Cancer Center of Excellence, University of Pittsburgh

Email: sunw@upmc.edu

Phone: 412-864-7764

Contact
Office: UPMC Cancer Pavilion
5150 Centre Avenue, Fifth Floor
Pittsburgh, PA 15232
 
Phone: 412-864-7764
Fax: 412-648-6579
E-mail: sunw@upmc.edu
Administrative Assistant:
Janice Kizior
Address: 5150 Centre Avenue, 5th floor
Pittsburgh, PA 15232
Email: Kiziorj@upmc.edu
Phone: 412-864-7764
Education and Training
Education
MD, Shanghai Medical University (Fudan University), 1982
MS, University of Nebraska, 1991
Training
Post-doc researcher, University of Pennsylvania, 1995
Residency - Internal Medicine, Loyola University Medical Center, 1998
Fellowship- Hematology-Oncology, University of Pennsylvania, 2001
Research Interest
Focus is on the treatment and clinical research of GI malignancies, mainly on the development of new drugs and biologic/targeted oriented agends in treatment/therapy (including translational research) of Gastrointestinal Malignancies with great experiences in the early phase clinical trial (phase I, II) designing, protocol development and conduction.
Clinical Interest
Dr. Sun's focus is on the treatment and clinical research of GI malignancies, mainly on the development of new drugs and biologic/targeted oriented agents in treatment/therapy (including translational research) of Gastrointestinal Malignancies with great experiences in the early phase clinical trial (phase I, II), designing, protocol development and conduction, and many of these have been published.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Annals of Oncology. 2016; 27(4): 680-7.
Schmoll HJ, Twelves C, Sun W, O'Connel M, Cartwright TH, McKenna EF, Saif WM, Lee S, Yothers G, Haller DG. Effect of adjuvant capecitabine ± oxaliplatin or 5-fluorouracil ± oxaliplatin on survival endpoints in stage III colon cancer and the impact of oxaliplatin on post-relapse survival. Lancet Oncology. 2014; 15(13): 1481-92.
Sohal DS, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced and metastatic cholangiocarcinoma. Annuals of Oncology. 2013; 24(12): 3061-5.
Sun W, Metz J, Gallagher M, O'Dwyer PJ, Whittington R, Giantonio B, Haller DG. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-Xuorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. Cancer Chemotherapy and Pharmacology. 2010; 67(3): 621-7.
Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, Caparro M, Teitelbaum UR, Giantonio B, O'Dwyer PJ, Shaked A, Reddy R, Olthoff K. A phase II study of the combination of capecitabine, oxaliplatin and bevacizumab in treatment of advanced hepatocellular carcinoma. Cancer. 2011; 117(14): 3187-92.
Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). Journal of Clinical Oncology. 2010; 28(18): 2947-51.
Sun W, Hewitt MR, Theodor M, Hershock D, Haller D. A phase I study of Irinotecan and fixed-dose rate gemcitabine in advanced pancreatic and biliary cancer. Cancer. 2007; 110(12): 2768-74.
Sun W, Lipsitz S, Catalano P, Haller D. Phase II/III Study of Doxorubicin with 5-Fluorouracil versus Sreptozocin with 5-Fluorouracil versus Dacarbaxine in the Treatment of Advanced Carcinoid Tumors E1281: A Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 2005; 23: 4897-4904.
Sun W, Whittington R, Gallagher M, O'Dwyer P, Giantonio B, Mets J, Haller D. Concurrent RT with 5-FU/Epirubicin and Cisplatin or Irinotecan for Locally Advanced Upper GI Adenocarcinoma. Oncology. 2004; 18(14): 39-42.
Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller DG, Algazy K, Giantonio B, Alila H, O'Dwyer PJ. Phase I and pharmacokinetic trail of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clinical Cancer Research. 2002; 8(1): 3100-3104.
Notable Achievements
University of Pittsburgh Hematology-Oncology, Dr. G. David Roodman Excellence in Mentoring Award, 2015
Newsweek Health: Top Cancer Doctors, 2015
Dan Von Hoff Award, Annual AACR/ASCO Clinical Research Development Workshop, VAIL CO, 2015